Need more? Try out  Advanced Search (20+ criteria)»

logo

Last Update

This profile was last updated on 12/22/2016 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong David Enscore?

David J. Enscore

Principal Scientist

4P Therapeutics LLC

HQ Phone:  (770) 263-1900

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

4P Therapeutics LLC

680 Engineering Dr, Suite 150

Norcross, Georgia,30092

United States

Company Description

4P Therapeutics is a private company focused on the research and development of novel drug delivery technologies and novel drug delivery based therapeutics. The company has capabilities for developing pharmaceutical products from pre-clinical testing to clinic...more

Background Information

Employment History

Vice President of Research and Development

Micell Technologies Inc


Senior Vice President Product Research and Development

Altea Therapeutics Corporation


Development

ALZA Corporation


Web References(22 Total References)


Leadership - 4P Therapeutics

www.4ptherapeutics.com [cached]

David Enscore, Ph.D.
Principal Scientist David J. Enscore advises 4P Therapeutics technology selection, product design goals, and analyzes results from product development studies. Over the last several years, he has provided product development direction to the pharmaceutical and medical device industries on a consulting basis. His focus is on controlled drug delivery products in general with a strong emphasis on transdermal drug delivery systems. In a consulting role, he served as Interim Vice President of R&D at Micell Technologies, a company developing a sirolimus eluting, bioabsorbable polymer coated coronary artery stent. He has served as an expert witness in several patent litigation cases involving transdermal technology. Prior to starting his consulting business, Dr. Enscore was Senior Vice President, Product Research and Development at Altea Therapeutics and was responsible for all product development activities including pharmaceutical science, engineering, clinical R&D, quality assurance, and regulatory affairs. Before joining Altea Therapeutics, he held senior R&D positions at Spherics, Incorporated, an advanced oral drug delivery company and Focal, Incorporated, a company that developed resorbable tissue sealants. Prior to this, Dr. Enscore worked extensively in transdermal drug delivery, in various scientific and management positions, at Alza Corporation. At Alza, he lead the development of Nicoderm® CQ (transdermal nicotine), the second generation testosterone transdermal system (Testoderm® TTS), and the Actisite® tetracycline periodontal fiber. He has been granted 25 U.S. patents in controlled drug delivery and biodegrabable polymers. Dr. Enscore received a BS and a PhD in Chemical Engineering, with a minor in Polymer Science, from North Carolina State University.


www.4ptherapeutics.com

David Enscore, Ph.D.
Senior Scientific Advisor David J. Enscore advises 4P Therapeutics technology selection, product design goals, and analyzes results from product development studies. Over the last several years, he has provided product development direction to the pharmaceutical and medical device industries on a consulting basis. His focus is on controlled drug delivery products in general with a strong emphasis on transdermal drug delivery systems. In a consulting role, he served as Interim Vice President of R&D at Micell Technologies, a company developing a sirolimus eluting, bioabsorbable polymer coated coronary artery stent. He has served as an expert witness in several patent litigation cases involving transdermal technology. Prior to starting his consulting business, Dr. Enscore was Senior Vice President, Product Research and Development at Altea Therapeutics and was responsible for all product development activities including pharmaceutical science, engineering, clinical R&D, quality assurance, and regulatory affairs. Before joining Altea Therapeutics, he held senior R&D positions at Spherics, Incorporated, an advanced oral drug delivery company and Focal, Incorporated, a company that developed resorbable tissue sealants. Prior to this, Dr. Enscore worked extensively in transdermal drug delivery, in various scientific and management positions, at Alza Corporation. At Alza, he lead the development of Nicoderm® CQ (transdermal nicotine), the second generation testosterone transdermal system (Testoderm® TTS), and the Actisite® tetracycline periodontal fiber. He has been granted 25 U.S. patents in controlled drug delivery and biodegrabable polymers. Dr. Enscore received a BS and a PhD in Chemical Engineering, with a minor in Polymer Science, from North Carolina State University.


About Altea Therapeutics

www.alteatech.com [cached]

David EnscoreSenior Vice PresidentProduct Research & Development


Life Science Partner | David Enscore to Direct Product Research and Development at Altea Therapeutics

lifesciencepartner.com [cached]

David Enscore to Direct Product Research and Development at Altea Therapeutics
Life Science Partner announces the placement of Dr. David J. Enscore as senior vice president, product research and development with Altea Therapeutics in Atlanta. As an integral part of Altea's executive leadership, the 20-year industry veteran will direct pharmaceutical and clinical product development while playing an important role in identifying and pursuing strategy. Altea Therapeutics works with the pharmaceutical and biotechnology industries to develop alternatives for medicine and vaccine delivery. "When we introduced David to Altea, he was very impressed with the company and its microporation technology," says Life Science Partner Founder and President Thomas H. Callaway. Enscore comes from Spherics, a Rhode Island-based early phase drug delivery company using bioadhesive polymers and nanoencapsulation to improve the oral bioavailability of therapeutic agents. As vice president of R&D there, he was responsible for all scientific and technical operations the from the company's inception. Later, Enscore assumed general management responsibilities as well. With Focal, Inc., a medical device company commercializing resorbable surgical sealants and drug delivery platform polymers, he served as vice president and guided all materials-related activities, including all research and development activities related to Focal's core polymer technologies. During a 16-year career at ALZA Corporation, where he began his career as a chemical engineer, Enscore held the titles of executive director, transdermal product development; director, new product discovery; director, physical sciences; and others. At ALZA, he managed the development of four controlled release pharmaceuticals including the NicoDerm CQ patch. Enscore is an inventor on 24 U.S. patents in drug delivery and medical devices. Enscore earned both his doctorate in chemical engineering (with a minor in polymer science) and his bachelor's in chemical engineering at North Carolina State University.


Life Science Partner | Jeanne Forbis Selected to Lead Medtronic Global Public and Media Relations

lifesciencepartner.com [cached]

David Enscore to Direct Product Research and Development at Altea Therapeut...Medtronic Selects Lothar Krinke to Direct Biotechnology Initiatives


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory